Corrections:

Nicole Golob-Schwarzl^1,2, Caroline Schweiger¹, Carina Koller¹, Stefanie Krassnig¹, Margit Gogg-Kamerer¹, Nadine Gantenbein^1,2, Anna M. Toeglhofer¹, Christina Wodlej^1,2, Helmut Bergler³, Brigitte Pertschy³, Stefan Uranitsch⁴, Magdalena Holter⁵, Amin El-Heliebi⁶, Julia Fuchs⁶, Andreas Punschart⁷, Philipp Stiegler⁷, Marlen Keil⁸, Jens Hoffmann⁸, David Henderson⁹, Hans Lehrach¹⁰, Christoph Reinhard¹¹, Christian Regenbrecht¹², Rudolf Schicho¹³, Peter Fickert¹⁴, Sigurd Lax¹⁵ and Johannes Haybaeck^1,2,16

¹Institute of Pathology, Medical University of Graz, Graz, Austria
²Center for Biomarker Research in Medicine, Graz, Austria
³Institute of Molecular Biosciences, Karl-Franzens-University of Graz, Graz, Austria
⁴Department of Surgery, Hospital Brothers of Charity Graz, Graz, Austria 5
⁵Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
⁶Institute of Cell Biology, Histology and Embryology, Medical University Graz, Graz, Austria
⁷Department of Surgery, Medical University of Graz, Graz, Austria
⁸Experimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Berlin, Germany
⁹Bayer AG, Berlin, Germany
¹⁰Max Planck Institute for Molecular Genetics, Berlin, Germany
¹¹Eli Lilly & Company, Indianapolis, USA
¹²Cpo – cellular phenomics & oncology Berlin-Buch GmbH, Berlin, Germany
¹³Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
¹⁴Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria
¹⁵Department of Pathology, Hospital Graz South-West, Austria
¹⁶Department of Pathology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

Published: February 02, 2023

Copyright: © 2023 Golob-Schwarzl et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4A, the image of the immunoblot for row ‘elF1’ in the CC column is an accidental duplicate of the ‘elF3B’ image in the ‘RC’ column of Figure 3A. The corrected Figure 4, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:101224–101243. DOI: https://doi.org/10.18632/oncotarget.20642

Figure 4: eIF1, eIF5 and eIF6 expression levels in low and high grade CC and RC. (A) Western blot of eIF1, eIF5 and eIF6 from LG and HG CC and RC NNT. Equal amounts of protein from each pair were resolved on SDS PAGE and immunoblotted with antibodies directed against eIF1, eIF5, eIF6 and β-actin (loading control). (B) qRT-PCR of eIF1, eIF5 and eIF6 from LG and HG CC and RC compared to NNT. Three independent experiments were carried out. Bars represent mean ± SEM. ***p < 0.01, ***p < 0.001. Statistical analysis: 2-way ANOVA with Bonferroni posttest.